List of Excipients in Branded Drug ANGIOMAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	ANGIOMAX	bivalirudin	0781-3447	MANNITOL
Sandoz Inc	ANGIOMAX	bivalirudin	0781-3447	SODIUM HYDROXIDE
The Medicines Company	ANGIOMAX	bivalirudin	65293-001	MANNITOL
The Medicines Company	ANGIOMAX	bivalirudin	65293-001	SODIUM HYDROXIDE
MAIA Pharmaceuticals Inc	ANGIOMAX RTU	bivalirudin	70511-141	ACETIC ACID
MAIA Pharmaceuticals Inc	ANGIOMAX RTU	bivalirudin	70511-141	HYDROCHLORIC ACID
MAIA Pharmaceuticals Inc	ANGIOMAX RTU	bivalirudin	70511-141	POLYETHYLENE GLYCOL 400

Last updated: August 21, 2026

Angiomax, the branded bivalirudin injection, has limited remaining product-level exclusivity value but retains commercial opportunity through excipient-enabled reformulation. The strongest opportunities are ready-to-use presentations, lower-concentration premixes, improved reconstitution systems, and hospital workflow products that reduce preparation errors. The active ingredient is a synthetic peptide anticoagulant, so biosimilar risk is not relevant; generic injectable competition and procurement pricing are the primary threats.

Angiomax Excipient Strategy and Commercial Opportunities for Bivalirudin Injection

What is Angiomax and how is it formulated?

Angiomax is the brand name for bivalirudin, a direct thrombin inhibitor used primarily during percutaneous coronary intervention. The product is supplied as a sterile lyophilized powder in a 250 mg single-dose vial.

The labeled formulation contains:

Component	Function
Bivalirudin trifluoroacetate	Active pharmaceutical ingredient
Mannitol	Bulking agent and lyoprotectant
Sodium hydroxide	pH adjustment during manufacture
Sterile water for injection	Reconstitution diluent, supplied separately by the healthcare provider
0.9% sodium chloride or 5% dextrose	Further dilution before administration

The reconstituted product has a concentration of approximately 5 mg/mL. For infusion, the reconstituted solution is diluted to approximately 5 mg/mL in 0.9% sodium chloride or 5% dextrose, according to the prescribing information. The product is administered intravenously and requires weight-based dosing and preparation in a hospital or procedural setting. [1]

The formulation is designed around peptide stability, sterile manufacturing, rapid dissolution, and compatibility with common intravenous diluents. Mannitol supports the cake structure of the lyophilized product and helps preserve the peptide during freeze-drying. The product does not rely on a complex excipient system.

What excipient strategy does Angiomax use?

Angiomax uses a minimal excipient strategy rather than a differentiated delivery platform. The commercial formulation has four practical design objectives:

1. Maintain bivalirudin stability during lyophilization and storage.
2. Produce a rapidly reconstituted sterile cake.
3. Avoid excipients that create injectable safety or compatibility issues.
4. Permit dilution in standard hospital fluids.

The limited excipient load is commercially relevant. Bivalirudin is administered in acute-care environments where clinicians favor predictable preparation, short handling times, and compatibility with existing infusion systems. A reformulation that adds excipients without improving preparation or stability would have limited value.

Why mannitol is commercially important

Mannitol is the main functional excipient in the Angiomax vial. In a lyophilized peptide product, mannitol can provide:

• Cake structure.
• Improved visual appearance.
• Controlled collapse behavior during lyophilization.
• A crystalline or partially crystalline matrix that affects drying and reconstitution.
• Reduced dependence on a larger excipient system.

A successor formulation could evaluate mannitol against sucrose, trehalose, glycine, histidine, citrate, or combinations of bulking and stabilizing agents. The commercial objective would not be to replace mannitol automatically. It would be to improve one or more measurable attributes, such as reconstitution time, stability after reconstitution, vial fill efficiency, or tolerance to temperature excursions.

What formulations are protected by Angiomax patents?

Historical Angiomax patent protection covered bivalirudin and its use rather than a high-value, differentiated excipient platform. The principal branded product patents expired before the current generic market matured. Current commercial protection therefore depends more on regulatory status, manufacturing know-how, product presentation, and customer contracts than on the original Angiomax formulation.

The relevant IP categories are:

IP category	Commercial relevance for Angiomax
Composition of matter	Historical protection for bivalirudin; no longer the main barrier
Method of use	Historical protection for anticoagulation during PCI and related procedures
Lyophilization cycle	Potentially protectable if tied to defined product attributes
Excipient composition	Potential opportunity for a new formulation
Reconstitution system	Potential opportunity for a kit, dual-chamber container, or integrated diluent
Ready-to-use solution	Potential opportunity if stability supports a commercial shelf life
Manufacturing process	Important for peptide purity, aggregation control, and batch consistency
Device compatibility	Potential protection for administration sets or co-packaged systems

An excipient patent would need more than a conventional list of mannitol, buffer, and water. A stronger formulation patent would link the excipient system to unexpected technical results, such as longer refrigerated stability, reduced aggregation, faster reconstitution, or improved potency retention after dilution.

When did Angiomax lose exclusivity?

Angiomax lost meaningful small-molecule exclusivity after expiration of its principal patents and FDA regulatory exclusivity. Generic bivalirudin injection products subsequently entered the U.S. market.

The product is not a biologic. It is a synthetic peptide drug regulated as a drug product, so the relevant competition is abbreviated new drug application competition rather than biosimilar competition. FDA-approved generic bivalirudin products can rely on the reference product’s safety and efficacy findings while demonstrating pharmaceutical equivalence and bioequivalence or other applicable requirements. [2]

The commercial result is a shift from patent-led pricing to hospital purchasing economics. A branded product must justify a premium through one or more of the following:

• Lower preparation labor.
• Reduced medication-error risk.
• Lower vial waste.
• More reliable supply.
• Longer in-use stability.
• Easier inventory management.
• Compatibility with automated compounding systems.
• Lower total cost per procedure.

What is the Orange Book status of Angiomax?

Angiomax has historically been listed in FDA’s Orange Book as the reference product for bivalirudin injection. Orange Book listings identify the reference product, approved dosage form, route, and any patents or exclusivity that affect abbreviated applications. [3]

For current commercial analysis, the important point is that the original Angiomax patent estate does not provide the same barrier that it provided during the branded product’s launch period. Any current Orange Book strategy would depend on newly approved patents associated with a later formulation, delivery presentation, or method of use. A conventional generic vial using the established bivalirudin formulation is unlikely to obtain durable differentiation from the legacy brand formulation alone.

Which companies are challenging Angiomax?

Competition has come primarily from generic injectable manufacturers rather than biosimilar developers. Companies active in hospital injectable products have commercial advantages because they already possess:

• Sterile manufacturing capacity.
• FDA inspection history.
• Hospital purchasing relationships.
• Contracting infrastructure.
• Injectable peptide manufacturing expertise.
• Experience with short-margin products.

The competitive field can include both ANDA sponsors and authorized or private-label suppliers. The relevant commercial threat is not the number of approved labels alone. It is the number of suppliers able to maintain supply, meet hospital tenders, and support national distribution.

Paragraph IV litigation is most relevant when a generic applicant challenges an unexpired Orange Book patent. For the legacy Angiomax product, the central patent barriers have largely passed. A new formulation or delivery system could create a new Paragraph IV target if its patents are listed and remain unexpired. [3,4]

What generic entry risks exist for Angiomax?

Generic entry risk is high for the conventional 250 mg lyophilized vial. The product has a familiar presentation, established clinical use, and a straightforward hospital administration pathway.

High-risk areas for the branded product

Risk area	Assessment
Conventional 250 mg vial	High generic risk
Mannitol-based lyophilized formulation	High substitution risk
Standard saline or dextrose dilution	No meaningful differentiation
Ready-to-use premix	Lower immediate substitution risk if no equivalent generic exists
Dual-chamber or integrated-diluent product	Moderate competition, depending on approval status
Stability-enhanced formulation	Potentially defensible if supported by patents
Automated compounding-compatible presentation	Commercially differentiated but requires workflow adoption

Generic competition can produce rapid price erosion in hospital products. The effect is strongest when the product has a single active ingredient, no complex device, no proprietary administration system, and limited clinical differentiation.

What excipient reformulations could create commercial value?

Ready-to-use bivalirudin solution

A ready-to-use solution could eliminate vial reconstitution and reduce preparation steps. The main technical barrier is solution stability. Bivalirudin must remain within specifications for potency, degradation products, aggregation, visible and subvisible particles, and sterility throughout the proposed shelf life.

Potential excipient variables include:

• Low-concentration phosphate or histidine buffers.
• Tonicity agents.
• pH modifiers.
• Chelators where justified by degradation pathways.
• Surfactants if adsorption or aggregation occurs.
• Antioxidant systems if oxidation is a demonstrated liability.

The principal risks are peptide degradation, container interaction, adsorption to tubing, and loss of stability in common infusion fluids. A ready-to-use product would also require a suitable container-closure system, likely a vial, syringe, bag, or cartridge.

Premixed infusion bag

A premixed bag could be positioned for catheterization laboratories and cardiac procedure units. It could reduce preparation time and pharmacy compounding demand.

Commercial value would depend on:

• Stable concentration during storage.
• Acceptable bag material compatibility.
• Low extractables and leachables.
• A practical shelf life.
• Compatibility with infusion pumps.
• Reduced product waste.
• Clear differentiation from a conventional generic vial.

A premix may be more valuable operationally than a reformulated vial because it changes the hospital workflow. The tradeoff is higher manufacturing, packaging, shipping, and stability complexity.

Dual-chamber presentation

A dual-chamber vial, syringe, or bag could separate dry bivalirudin from the diluent until administration. This approach could preserve the stability advantages of a lyophilized product while eliminating manual reconstitution.

The IP opportunity would involve the combination of:

• Chamber geometry.
• Break-seal or transfer mechanism.
• Excipient composition.
• Reconstitution sequence.
• Product concentration.
• Device compatibility.

A dual-chamber system could support a stronger patent position than a simple excipient substitution because the protection would cover a product configuration and use process.

Faster-reconstituting lyophilized vial

A lower-cost opportunity is to retain the vial format while reducing reconstitution time. Possible approaches include:

• Modified mannitol-to-stabilizer ratios.
• Controlled cake porosity.
• Smaller particle size before filling.
• Optimized fill volume.
• Alternative bulking agents.
• Revised freezing and primary-drying cycles.
• Enhanced stopper and vacuum configuration.

This strategy can improve workflow without requiring a new container system. Its commercial value may be limited unless the time reduction is material and measurable in procedural settings.

How strong is the patent estate for an Angiomax reformulation?

The patent strength of an Angiomax reformulation depends on technical specificity. Broad claims to "bivalirudin plus a pharmaceutically acceptable excipient" would face substantial validity and obviousness risk because peptide formulations commonly use buffers, sugars, polyols, and surfactants.

A stronger estate would combine:

1. A narrow excipient range.
2. A defined bivalirudin concentration.
3. A specified pH.
4. A lyophilization or solution process.
5. A measurable stability result.
6. A commercial presentation tied to the formulation.
7. Data showing an unexpected advantage over Angiomax and generic bivalirudin.

Potential claim categories include:

• Composition claims.
• Lyophilized cake claims.
• Reconstituted solution claims.
• Premixed infusion-bag claims.
• Container-closure claims.
• Method-of-preparation claims.
• Method-of-use claims linked to reduced preparation error or improved administration.

Patent term should be modeled from the earliest effective nonprovisional filing date, with possible patent-term adjustment and, where applicable, patent-term extension. A formulation patent filed after generic entry would generally have to compete against published prior art, commercial products, and clinical-use disclosures.

What FDA regulatory pathway applies to a new Angiomax formulation?

A conventional generic bivalirudin vial would generally proceed through an ANDA if it matches the reference product in active ingredient, dosage form, route, strength, and other applicable requirements.

A materially different formulation could require a 505(b)(2) application rather than an ANDA. The pathway becomes more plausible when the product changes:

• Concentration.
• Dosage form.
• Container system.
• Diluent.
• Route or administration method.
• Stability profile.
• Labeling tied to a new preparation process.

A 505(b)(2) strategy can support three commercial objectives:

• Regulatory reliance on existing bivalirudin data.
• Approval of a differentiated presentation.
• Potentially separate intellectual-property protection.

The formulation must still establish quality, safety, and efficacy for its intended presentation. FDA review would focus on peptide characterization, impurities, aggregation, sterility assurance, container compatibility, and in-use stability. [2,5]

What manufacturing and IP barriers affect bivalirudin excipients?

The principal manufacturing barrier is not excipient availability. Mannitol, sugars, buffers, and common injectable excipients are widely available. The barrier is reproducible manufacture of a sterile peptide product with controlled impurity and aggregation profiles.

Critical process areas include:

• Peptide synthesis and impurity purge.
• Trifluoroacetate removal or control.
• Bulk solution hold time.
• Sterile filtration.
• Aseptic filling.
• Freezing profile.
• Primary and secondary drying.
• Residual moisture.
• Reconstitution performance.
• Container-closure integrity.
• Shipping-temperature qualification.

A formulation that performs well in laboratory vials may not scale economically. Lyophilization cycle time, batch size, and filling-line throughput can materially affect cost of goods. For a low-margin generic product, these factors can eliminate the commercial benefit of a technically superior formulation.

How does Angiomax compare with competing injectable anticoagulants?

Product	Active ingredient	Formulation opportunity	Main commercial issue
Angiomax	Bivalirudin	Ready-to-use or workflow-focused presentation	Generic price pressure
Heparin sodium	Unfractionated heparin	Standardized concentrations and safety packaging	Broad generic supply and low unit cost
Enoxaparin	Low-molecular-weight heparin	Prefilled syringes and dose presentation	Established branded and generic competition
Argatroban	Argatroban	Premix and stability improvements	Smaller market and competing indications
Fondaparinux	Fondaparinux	Prefilled delivery systems	Different clinical use and administration profile

Bivalirudin’s commercial position is strongest where rapid, controlled anticoagulation is valued and bleeding management or heparin-related considerations affect product selection. Its market is narrower than that of unfractionated heparin, so a reformulation must produce workflow or safety value rather than rely only on chemical novelty.

What licensing deals could support an Angiomax lifecycle strategy?

A lifecycle program could involve three licensing components:

Excipient and formulation licensing

A sponsor could license a proprietary stabilizer system, lyophilization process, or peptide formulation platform. The license should include rights to injectable use, freedom-to-operate review, and data transfer for scale-up.

Container and delivery licensing

A dual-chamber syringe, premixed bag, or closed-system transfer device could be licensed from a specialty device company. The commercial advantage would come from reducing preparation steps rather than from changing the active ingredient.

Hospital channel licensing

A branded manufacturer could partner with a contract manufacturer or hospital injectable supplier to obtain sterile capacity and institutional contracting reach. This may be more important than owning a novel excipient, because hospital adoption depends on supply reliability and procurement economics.

License value would depend on exclusivity, geographic scope, patent term, regulatory ownership, manufacturing rights, and whether the partner can support FDA inspection and commercial-scale aseptic production.

What is the revenue exposure for Angiomax?

Revenue exposure is concentrated in procedural hospital use. The product does not have the broad prescription volume of chronic cardiovascular medicines. Commercial sensitivity therefore depends on:

• Number of PCI procedures.
• Use of bivalirudin relative to heparin.
• Hospital formulary decisions.
• Generic price discounts.
• Supply continuity.
• Availability of competing anticoagulants.
• Any future use in structural-heart or other catheter-based procedures.

The revenue risk from generic entry is high for the standard vial and lower for a differentiated presentation with a defensible reimbursement or purchasing advantage. A ready-to-use formulation may support premium pricing only if the hospital can quantify labor savings, fewer preparation errors, lower waste, or improved procedure throughput.

What is the most attractive commercial strategy for Angiomax?

The strongest strategy is a staged formulation program:

1. Retain the established bivalirudin dose and clinical use.
2. Develop a ready-to-use or dual-chamber presentation.
3. Screen excipient systems for solution stability and peptide aggregation.
4. Generate comparative data against Angiomax and generic bivalirudin.
5. File composition, process, container, and use patents before public disclosure.
6. Use a 505(b)(2) pathway if the presentation is materially different.
7. Target catheterization laboratories, hospital pharmacies, and automated compounding channels.
8. Price against total preparation cost rather than vial price alone.

A simple excipient substitution is unlikely to create durable value. A formulation-device combination that removes reconstitution and dilution steps has a stronger commercial rationale and potentially stronger IP protection.

Key Takeaways

• Angiomax is a lyophilized 250 mg bivalirudin injection containing mannitol as the principal excipient.
• The legacy formulation is vulnerable to generic substitution and hospital price competition.
• Biosimilar competition does not apply because bivalirudin is regulated as a synthetic peptide drug, not a biologic.
• The most credible lifecycle opportunities are ready-to-use solutions, premixed bags, dual-chamber systems, and faster-reconstituting vials.
• New excipient patents require narrow compositions tied to measurable stability or handling advantages.
• A materially differentiated presentation may be better suited to a 505(b)(2) application than an ANDA.
• The commercial case depends on reducing preparation burden, waste, error risk, and supply disruption.
• The strongest opportunity is a formulation-device product that improves hospital workflow while preserving the established bivalirudin dosing framework.

FAQs

Can mannitol be replaced in an Angiomax reformulation?

Yes. Mannitol could be evaluated against sucrose, trehalose, glycine, buffers, or combinations of stabilizers and bulking agents. Replacement would need to improve a defined quality attribute, such as reconstitution, stability, cake structure, or aggregation control.

Could a bivalirudin premix obtain new patent protection?

Yes. A premix could support patents covering the concentration, excipient system, container, stability period, and method of administration. Patent strength would depend on technical results that are not predictable from existing bivalirudin products.

Is a bivalirudin ready-to-use syringe commercially attractive?

Potentially. A prefilled syringe could remove reconstitution and reduce pharmacy workload. The principal barriers are solution stability, peptide adsorption, container compatibility, sterility, and procedural dosing requirements.

Would a new Angiomax formulation qualify for pediatric exclusivity?

Pediatric exclusivity is not automatic. It requires an FDA-requested pediatric study program and completion of the applicable statutory requirements. A new formulation would not receive pediatric exclusivity solely because it changes excipients or presentation. [6]

Can generic bivalirudin manufacturers challenge a new Angiomax formulation?

Yes. A generic sponsor could challenge applicable patents through a Paragraph IV certification or pursue an alternative formulation that does not infringe the listed claims. The scope and timing of the challenge would depend on the patents listed for the new product and the approved labeling.

References

1. DailyMed. (n.d.). Angiomax: Bivalirudin injection, powder, lyophilized, for solution prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug product with therapeutic equivalence evaluations, patent and exclusivity information. FDA.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA.

5. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.

6. U.S. Food and Drug Administration. (2024). Pediatric exclusivity provisions. FDA.